13,969 Shares in Anixa Biosciences, Inc. (NASDAQ:ANIX) Acquired by Concorde Asset Management LLC

Concorde Asset Management LLC acquired a new position in Anixa Biosciences, Inc. (NASDAQ:ANIX) during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund acquired 13,969 shares of the company’s stock, valued at approximately $31,000.

Other institutional investors have also recently added to or reduced their stakes in the company. Staley Capital Advisers Inc. acquired a new position in Anixa Biosciences in the first quarter valued at approximately $31,000. Simplicity Wealth LLC acquired a new position in Anixa Biosciences in the first quarter valued at approximately $44,000. Nations Financial Group Inc. IA ADV lifted its stake in Anixa Biosciences by 50.0% in the second quarter. Nations Financial Group Inc. IA ADV now owns 22,500 shares of the company’s stock valued at $50,000 after buying an additional 7,500 shares during the period. Finally, Virtu Financial LLC lifted its stake in Anixa Biosciences by 47.2% in the first quarter. Virtu Financial LLC now owns 16,156 shares of the company’s stock valued at $50,000 after buying an additional 5,183 shares during the period. 29.13% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In other news, Director Lewis H. Titterton, Jr. acquired 21,646 shares of the firm’s stock in a transaction dated Tuesday, July 30th. The stock was purchased at an average price of $3.06 per share, for a total transaction of $66,236.76. Following the completion of the acquisition, the director now directly owns 890,754 shares in the company, valued at approximately $2,725,707.24. The purchase was disclosed in a filing with the SEC, which is available at the SEC website. Corporate insiders own 22.60% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages have issued reports on ANIX. EF Hutton Acquisition Co. I raised Anixa Biosciences to a “strong-buy” rating in a research note on Wednesday, August 7th. HC Wainwright reissued a “buy” rating and issued a $7.00 price target on shares of Anixa Biosciences in a research note on Tuesday.

Anixa Biosciences Stock Down 0.9 %

NASDAQ ANIX opened at $3.42 on Friday. The company has a market cap of $109.46 million, a price-to-earnings ratio of -9.14 and a beta of 0.86. Anixa Biosciences, Inc. has a 52 week low of $2.14 and a 52 week high of $5.13. The business has a 50 day moving average price of $3.16 and a 200-day moving average price of $2.99.

Anixa Biosciences (NASDAQ:ANIX) last released its quarterly earnings data on Friday, September 6th. The company reported ($0.10) EPS for the quarter, beating the consensus estimate of ($0.11) by $0.01. On average, equities research analysts anticipate that Anixa Biosciences, Inc. will post -0.43 earnings per share for the current year.

About Anixa Biosciences

Anixa Biosciences, Inc, a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer.